Ulcerative Colitis

Latest News

Upadacitinib Meets Endpoints in Ulcerative Colitis Maintenance Trial

By

Brian Park, PharmD

A significantly greater proportion of patients treated with upadacitinib 15mg and 30mg achieved clinical remission at week 52 compared with those receiving placebo.

Bacterial Biofilms Frequently Identified During Endoscopy Among Patients With IBS or UC

By

Jessica Nye, PhD

Researchers analyzed the presence and effect of mucosal biofilms in patients with irritable bowel syndrome and ulcerative colitis.

Vedolizumab Improves Histologic Remission, Disease Activity Better Than Adalimumab in UC

By

Brandon May

Investigators compared rates of histologic remission and disease activity in patients with UC treated with vedolizumab vs adalimumab.

Adalimumab Shows Safety and Efficacy in Pediatric Patients With UC

By

Tylar Stanley

Investigators evaluated the safety and efficacy of adalimumab in pediatric patients with moderate to severe ulcerative colitis.

Upadacitinib Improves Symptoms of UC

By

Tylar Stanley

Researchers aimed to evaluate how bowel urgency and abdominal pain may improve with upadacitinib treatment, as indicted by health related quality of life outcomes.

Filgotinib Shows Efficacy in Ulcerative Colitis

By

Vincent Soreca

Researchers analyzed the safety and efficacy of filgotinib in patients with moderately to severely active ulcerative colitis.

Vedolizumab Shows Better Safety Profile Compared With Anti-TNFα in IBD

By

Vincent Soreca

Researchers compared the clinical effectiveness and safety profiles of vedolizumab and anti-TNFα agents in biologic-naïve adult patients with ulcerative colitis and Crohn disease.

Clinical Remission Observed With Ozanimod in Ulcerative Colitis Trial

By

Brian Park, PharmD

Positive topline results were announced from the phase 3 True North trial evaluating the efficacy of ozanimod as an induction and maintenance therapy for adults with moderate to severe ulcerative colitis.

Frequency of Tofacitinib-Linked Malignancy Events in UC

By

Rita Aghjayan

Researchers analyzed malignancy events and their relationship to tofacitinib treatment levels in patients with ulcerative colitis.

Addressing the “Therapeutic Ceiling” in Drug Discovery for UC

By

Emily Pond

Reviewers addressed potential reasons for the shortcomings of newer therapies and proposed solutions to increase treatment efficacy in ulcerative colitis.

Fecal Microbiota Transplant Improves UC Indices in Pediatric Patients

By

Brandon May

Investigators conducted a randomized controlled trial to assess the use of fecal microbiota transplants in children with ulcerative colitis.

Efficacy and Safety of Tofacitinib Re-Treatment for UC

By

Virginia A. Schad, PharmD, RPh

Investigators examined the safety and efficacy of tofacitinib re-treatment in patients with ulcerative colitis who underwent treatment interruption.

Patients With UC in Remission Who Continue Infliximab Have Significantly Higher Remission Rates

By

Colby Stong

Researchers compared outcomes and remission rates among patients with ulcerative colitis who continue or discontinue treatment with infliximab.

Zeposia Approved for Moderately to Severely Active Ulcerative Colitis

By

Diana Ernst, RPh

The FDA has approved Zeposia® (ozanimod) for moderately to severely active ulcerative colitis in adults.

Ozanimod Maintenance in Patients With UC Associated With CS-Free Remission

By

Bradley van Paridon

Researchers analyzed the rates of achieving corticosteroid-free remission in patients with ulcerative colitis receiving maintenance treatment with ozanimod vs placebo.

Tofacitinib for the Long-Term Maintenance of Remission in UC

By

Emily Pond

Researchers aimed to determine the safety and efficacy of tofacitinib in maintaining remission from ulcerative colitis over long-term follow up.

Diet-Gut Microbiome Associations and Patients With Intestinal Disease

By

Virginia A. Schad, PharmD, RPh

Researchers studied the interactions between diet, gut microbiota, and their functional ability to induce intestinal inflammation.

Anti-TNF Therapy Associated with Reduced Mortality in IBD

By

Vincent Soreca

Researchers aimed to examine the association of anti-TNF with reduced mortality relative to prolonged corticosteroid use in a cohort of veterans with IBD.

COVID-19 and IBD: Impact of Disease State and Biologics

By

C. Andrew Kistler, MD, PharmD

In patients with IBD, management of immunosuppressive regimens, as well as safety and efficacy of vaccines, has raised many questions during the COVID-19 pandemic.

Ustekinumab Dose Intensification is Safe and Effective in Patients With UC

By

Virginia A. Schad, PharmD, RPh

Researchers aimed to identify predictors and outcomes of ustekinumab dose intensification in 108 patients with ulcerative colitis.